Whole Exome Sequencing in Vaccine‐Induced Thrombotic Thrombocytopenia (VITT)

Background: In February 2021, a few cases of unusual, severe thrombotic events associated with thrombocytopenia reported after vaccination with ChAdOx1 nCoV‐19 (Vaxzevria) or with Johnson & Johnson’s Janssen vaccine raise concern about safety. The vaccine‐induced thrombotic thrombocytopenia (VIT...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2024-01, Vol.2024 (1), p.2860547
Main Authors: Giusti, Betti, Sticchi, Elena, Capezzuoli, Tommaso, Orsi, Rebecca, Squillantini, Lapo, Giannini, Marco, Suraci, Samuele, Rogolino, Angela Antonietta, Cesari, Francesca, Berteotti, Martina, Gori, Anna Maria, Lotti, Elena, Marcucci, Rossella
Format: Article
Language:English
Subjects:
Age
Antibodies
Blood platelets
Blood-brain barrier
Coagulation
Combined vaccines
Coronaviruses
COVID-19 vaccines
Cytosol
Drug dosages
Endothelial cells
Females
Fibrinogen
Genes
Genetic diversity
Genetic variance
Genomes
Genotyping
Glycosylation
Haplotypes
Hemorrhage
Immunoglobulin G
Molecular modelling
Nanoparticles
Nuclear reactions
Nucleotides
Ontology
Patients
Pharmacovigilance
Platelets
Proteins
Risk assessment
Severe acute respiratory syndrome coronavirus 2
Single-nucleotide polymorphism
Software
Thrombocytopenia
Thromboembolism
Thrombophilia
Thrombosis
Vaccines
Whole genome sequencing
Citations: Items that this one cites
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: In February 2021, a few cases of unusual, severe thrombotic events associated with thrombocytopenia reported after vaccination with ChAdOx1 nCoV‐19 (Vaxzevria) or with Johnson & Johnson’s Janssen vaccine raise concern about safety. The vaccine‐induced thrombotic thrombocytopenia (VITT) has been related to the presence of platelet‐activating antibodies directed against platelet Factor 4. Objectives: We investigated VITT subject genetic background by a high‐throughput whole exome sequencing (WES) approach in order to investigate VITT genetic predisposition. Methods: Six consecutive patients (females of Caucasian origin with a mean age of 64 years) were referred to the Atherothrombotic Diseases Center (Department of Experimental and Clinical Medicine, Azienda Ospedaliero‐Universitaria Careggi, Florence) with a diagnosis of definite VITT underwent WES analysis. WES analysis was performed on the Illumina NextSeq500 platform. Results: WES analysis revealed a total of 140,563 genetic variants. Due to VITT’s rare occurrence, we focused attention on rare variants. The global analysis of all high‐quality rare variants did not reveal a significant enrichment of mutated genes in biological/functional pathways common to patients analyzed. Afterwards, we focused on rare variants in genes associated with blood coagulation and fibrinolysis, platelet activation and aggregation, integrin‐mediated signaling pathway, and inflammation with particular attention to those involved in vascular damage, as well as autoimmune thrombocytopenia. According to ACMG criteria, 47/194 (24.2%) rare variants were classified as uncertain significance variants (VUS), whereas the remaining were likely benign/benign. Conclusion: WES analysis identifies rare variants possibly favoring the prothrombotic state triggered by the exposure to the vaccine. Functional studies and/or extensions to a larger number of patients might allow a more comprehensive definition of these molecular pathways.
ISSN:2314-6133
2314-6141
2314-6141
DOI:10.1155/2024/2860547